CA2678007A1 - Composes pyrrolo[2,3-b]pyridine, composes azaindoles utiles dans la synthese de ces composes pyrrolo[2,3-b]pyridine, leurs procedes de fabrication et leurs utilisations - Google Patents

Composes pyrrolo[2,3-b]pyridine, composes azaindoles utiles dans la synthese de ces composes pyrrolo[2,3-b]pyridine, leurs procedes de fabrication et leurs utilisations Download PDF

Info

Publication number
CA2678007A1
CA2678007A1 CA002678007A CA2678007A CA2678007A1 CA 2678007 A1 CA2678007 A1 CA 2678007A1 CA 002678007 A CA002678007 A CA 002678007A CA 2678007 A CA2678007 A CA 2678007A CA 2678007 A1 CA2678007 A1 CA 2678007A1
Authority
CA
Canada
Prior art keywords
pyrrolo
pyridine
group
pyrimidin
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002678007A
Other languages
English (en)
French (fr)
Inventor
Laurent Meijer
Benoit Joseph
Francois Liger
Bernard Marquet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite Pierre et Marie Curie
Universite Claude Bernard Lyon 1
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2678007A1 publication Critical patent/CA2678007A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002678007A 2007-02-16 2008-02-14 Composes pyrrolo[2,3-b]pyridine, composes azaindoles utiles dans la synthese de ces composes pyrrolo[2,3-b]pyridine, leurs procedes de fabrication et leurs utilisations Abandoned CA2678007A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0701138 2007-02-16
FR0701138A FR2912744B1 (fr) 2007-02-16 2007-02-16 Composes pyrrolo°2,3-b!pyridine,composes azaindoles utiles dans la synthese de ces composes pyrrolo°2,3-b!pyridine, leurs procedes de fabrication et leurs utilisations.
PCT/FR2008/000197 WO2008129152A1 (fr) 2007-02-16 2008-02-14 Composes pyrrolo[2,3-b]pyridine, composes azaindoles utiles dans la synthese de ces composes pyrrolo[2,3-b]pyridine, leurs procedes de fabrication et leurs utilisations

Publications (1)

Publication Number Publication Date
CA2678007A1 true CA2678007A1 (fr) 2008-10-30

Family

ID=38515529

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002678007A Abandoned CA2678007A1 (fr) 2007-02-16 2008-02-14 Composes pyrrolo[2,3-b]pyridine, composes azaindoles utiles dans la synthese de ces composes pyrrolo[2,3-b]pyridine, leurs procedes de fabrication et leurs utilisations

Country Status (6)

Country Link
US (1) US20100184790A1 (enExample)
EP (1) EP2125803B1 (enExample)
JP (1) JP2010518153A (enExample)
CA (1) CA2678007A1 (enExample)
FR (1) FR2912744B1 (enExample)
WO (1) WO2008129152A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2320895A2 (en) * 2008-07-03 2011-05-18 Exelixis, Inc. Cdk modulators
US8435980B2 (en) * 2009-07-15 2013-05-07 Abbvie Inc. Pyrrolopyridine inhibitors of kinases
EP2867236B1 (en) 2012-06-29 2017-06-14 Pfizer Inc Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
FR2999575A1 (fr) * 2012-12-18 2014-06-20 Centre Nat Rech Scient 3,5-diaryl-azaindoles comme inhibiteurs de la proteine dyrk1a pour le traitement des deficiences cognitives liees au syndrome de down et a la maladie d'alzheimer
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
US9580416B2 (en) 2014-07-02 2017-02-28 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
CN108137586B (zh) 2015-09-14 2021-04-13 辉瑞大药厂 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
FR3041640B1 (fr) * 2015-09-30 2019-05-17 Les Laboratoires Servier NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
WO2017094026A1 (en) 2015-11-30 2017-06-08 Council Of Scientific & Industrial Research 3-pyrimidinyl pyrrolo [2,3-b] pyridine as new anticancer agents and the process for the preparation thereof
WO2018136202A2 (en) * 2016-12-23 2018-07-26 Plexxikon Inc. Compounds and methods for cdk8 modulation and indications therefor
AU2018239798B2 (en) * 2017-03-23 2020-08-27 Daegu Gyeongbuk Institute Of Science And Technology Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases
EP3668882A1 (en) * 2017-08-18 2020-06-24 Cancer Research Technology Limited Pyrrolo[2,3-b]pyridine compounds and their use in the treatment of cancer
CN110759892B (zh) * 2018-07-26 2022-09-13 南开大学 Meridianin类衍生物及其制备和在防治植物病毒病菌病中的应用
CN109096257B (zh) * 2018-08-09 2020-02-21 山东博苑医药化学有限公司 Meridianin类生物碱及其衍生物在防治植物病毒病菌病中的应用
JP7564983B2 (ja) 2019-01-18 2024-10-10 ボロノイ インコーポレイテッド ピロロピリジン誘導体およびタンパク質キナーゼ関連疾患の予防または治療での使用のためのその用途
CN109879874A (zh) * 2019-03-05 2019-06-14 常州大学 一种Meriolin的合成方法
KR20220081631A (ko) 2020-12-09 2022-06-16 보로노이 주식회사 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도
WO2022245776A1 (en) * 2021-05-20 2022-11-24 Saint John's Cancer Institute Anti-cdk inhibitors for cancer treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7855205B2 (en) * 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
WO2006124863A2 (en) * 2005-05-16 2006-11-23 Irm Llc Pyrrolopyridine derivatives as protein kinase inhibitors
BRPI0619184A2 (pt) * 2005-11-30 2011-09-13 Hoffmann La Roche 3-amino-2-arilpropil azaindóis e usos destes

Also Published As

Publication number Publication date
WO2008129152A1 (fr) 2008-10-30
EP2125803B1 (fr) 2013-04-10
FR2912744B1 (fr) 2012-09-07
FR2912744A1 (fr) 2008-08-22
US20100184790A1 (en) 2010-07-22
JP2010518153A (ja) 2010-05-27
EP2125803A1 (fr) 2009-12-02

Similar Documents

Publication Publication Date Title
CA2678007A1 (fr) Composes pyrrolo[2,3-b]pyridine, composes azaindoles utiles dans la synthese de ces composes pyrrolo[2,3-b]pyridine, leurs procedes de fabrication et leurs utilisations
DE69815317T2 (de) Pyrrolo[2,3-d]pyrimidine und ihre verwendung als tyrosinkinase-inhibitoren
JP5820921B2 (ja) １，２−二置換複素環式化合物
EP3024833B1 (fr) Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
JP5943053B2 (ja) フェノキシメチル複素環化合物
EP4285996A2 (en) Inhibitors of activin receptor-like kinase
JP2021105002A (ja) イミダゾピリダジン化合物
TW200520758A (en) Novel pharmaceuticals
EP3697786B1 (en) Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
TW201213324A (en) Fused heterocyclic compounds
FR2906250A1 (fr) Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique
CA2766909C (fr) Nouveaux derives de 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one,leur preparation et leur utilisation pharmaceutique
WO2004043936A1 (ja) Ｐｌｋ阻害剤
JP2020524148A (ja) 置換５−シアノインドール化合物及びその使用
CN103974954A (zh) 调节激酶的化合物、含有它们的组合物及其用途
JP2021535154A (ja) バニン阻害剤としてのヘテロ芳香族化合物
JP2008533172A (ja) チロシン／スレオニンキナーゼ阻害剤、特にＢ−ＲＡＦキナーゼ阻害剤としての、Ｎ−［３−（１−アミノ−５，６，７，８−テトラヒドロ−２，４，４ｂ−トリアザフルオレン−９−イル）−フェニル］ベンズアミド
US9994590B2 (en) Substituted [1,2,4]triazolo[1,5-a]pyrazines as phosphodiesterase inhibitors
TW201643143A (zh) 抑制氧化壓迫引發的神經細胞死亡之化合物
KR102171706B1 (ko) 포스포디에스테라아제 10 효소의 억제제
HK1200815A1 (en) [1,2,4]triazolopyridines and their use as phospodiesterase inhibitors
RU2833338C1 (ru) Конденсированное трициклическое соединение и его применение в медицине
TW202227447A (zh) 嘧啶酮類化合物及其用途
TW201211043A (en) Tetrahydro-imidazo[1,5-a]pyrazine derivatives salts, preparation process and pharmaceutical use thereof
JP2017075116A (ja) 新規縮合複素環化合物

Legal Events

Date Code Title Description
EEER Examination request
EEER Examination request

Effective date: 20121220

FZDE Discontinued

Effective date: 20150216